ArticleAlzheimer's research & therapy2010
Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice?
Article in Alzheimer's research & therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 51 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Brain Stimulation for Neurological Patients
DNS Cohort Study Aimed at Understanding the Pathophysiology of AD and AD Related Disorders (ADRD)
Who cites it
51 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence.Drugs & aging · 2015Pooled it
- Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials.PloS one · 2013Pooled it
- Measuring clinically relevant change in apathy symptoms in ADMET and ADMET 2.International psychogeriatrics · 2024Trial
- Trial
- Validation of the Erlangen Test of Activities of Daily Living in Persons with Mild Dementia or Mild Cognitive Impairment (ETAM).BMC geriatrics · 2016Trial
- [Cognitive stimulation and music intervention for people with dementia in nursing homes: A pilot study, problems and perspectives].Zeitschrift fur Gerontologie und Geriatrie · 2015Trial
- Activities of daily living in dementia: revalidation of the E-ADL Test and suggestions for further development.BMC psychiatry · 2012Trial
- Psychometric evaluation of the Norwegian version of the Threadgold Communication Tool.International journal of nursing studies advances · 2025Article
- Article
- Predictors of Cognitive Decline in Alzheimer's Disease: A Longitudinal Bayesian Analysis.Medicina (Kaunas, Lithuania) · 2025Article
- Neural Underpinnings of Learning in Dementia Populations: A Review of Motor Learning Studies Combined with Neuroimaging.Journal of cognitive neuroscience · 2024Review
- Shortening the Alzheimer's disease assessment scale cognitive subscale.European psychiatry : the journal of the Association of European Psychiatrists · 2024Article
- Development of the Forman Alzheimer's disease scale.Heliyon · 2023Article
- Development of a Rasch-Built Amyotrophic Lateral Sclerosis Impairment Multidomain Scale to Measure Disease Progression in ALS.Neurology · 2023Article
- The Global Deterioration Scale for Down Syndrome Population (GDS-DS): A Rating Scale to Assess the Progression of Alzheimer's Disease.International journal of environmental research and public health · 2023Article
- A task force for diagnosis and treatment of people with Alzheimer's disease in Latin America.Frontiers in neurology · 2023Review
- Can the fNIRS-derived neural biomarker better discriminate mild cognitive impairment than a neuropsychological screening test?Frontiers in aging neuroscience · 2023Article
- Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations.Translational neurodegeneration · 2022Review
- Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer's disease.Alzheimer's research & therapy · 2022Review
- Prefrontal functional connectivity analysis of cognitive decline for early diagnosis of mild cognitive impairment: a functional near-infrared spectroscopy study.Biomedical optics express · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionThe present review of Alzheimer's disease (AD) rating scales aims to outline the need for a new rating scale to be used in routine clinical practice for long-term medical care of AD patients. An ideal scale would be: 1) practical, easy and quick to administer for an experienced clinician; 2) validated for AD; 3) multi-domain: covering the AD-relevant areas of cognition, activities of daily living, behavior, communication/social interaction, and quality of life; 4) applicable to all AD severity stages; 5) able to monitor disease progression; and 6) sensitive to measure therapy effects.
methodsThe National Library of Medicines' MEDLINE database was searched for the years 1981 to September 2008, using a set of keywords aiming to select instruments which cover at least some of the requirements for an ideal practical AD scale for therapy evaluation. Measures for AD staging and screening tests were not considered for review.
resultsOf 1,902 articles resulting from the literature search, 68 relevant AD scales were identified. Most of them were scales that predominantly measure the severity of major dysfunctions in particular AD domains. Only five scales met some of the requirements for a practical multi-domain AD scale, but did not possess all required characteristics.
conclusionsDespite the multitude of AD scales for various purposes, there remains a need for a new multi-domain and easy to administer AD scale for assessment of disease progression and response to therapy in daily medical practice.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.